Coherus Oncology, Inc. (NASDAQ:CHRS) is a biopharmaceutical company focused on developing and commercializing innovative cancer therapies. The company operates in a competitive landscape alongside peers such as Atara Biotherapeutics, Inc. (ATRA), FibroGen, Inc. (FGEN), MacroGenics, Inc. (MGNX), CytomX Therapeutics, Inc. (CTMX), and Blueprint Medicines Corporation (BPMC). These companies are all engaged in the development of novel treatments in the oncology sector.
In evaluating Coherus Oncology's financial performance, the Return on Invested Capital (ROIC) is a critical metric. Coherus has a ROIC of -117.17%, which is significantly negative. This indicates that the company is not generating returns on its invested capital that exceed its cost of capital, which is a concerning sign for investors. The Weighted Average Cost of Capital (WACC) for Coherus is 9.41%, further highlighting the inefficiency in capital utilization.
Comparatively, Atara Biotherapeutics, Inc. (ATRA) demonstrates a strong financial position with a ROIC of 36.19% and a WACC of 6.36%. This results in a ROIC to WACC ratio of 5.69, indicating that Atara is generating returns significantly above its cost of capital. This efficient capital utilization makes Atara an attractive option for investors seeking growth potential in the biopharmaceutical sector.
On the other hand, FibroGen, Inc. (FGEN) and MacroGenics, Inc. (MGNX) face similar challenges to Coherus, with negative ROIC to WACC ratios of -16.73 and -5.71, respectively. These figures suggest that these companies are also struggling to generate sufficient returns on their invested capital, which could impact their long-term financial health and investment appeal.
CytomX Therapeutics, Inc. (CTMX) and Blueprint Medicines Corporation (BPMC) present a mixed picture. CytomX has a positive ROIC of 18.76% and a WACC of 14.58%, resulting in a ROIC to WACC ratio of 1.29. This indicates some level of efficiency in capital utilization. In contrast, Blueprint Medicines has a negative ROIC of -17.59% and a WACC of 8.26%, leading to a ROIC to WACC ratio of -2.13, suggesting challenges in generating returns above its cost of capital.
